Cargando…
IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules
Cisplatin-based chemotherapy is currently the most effective treatment regimen for non-small cell lung cancer (NSCLC), but eventually tumor resistance develops which limits its success. The potential implication of IL-6 signaling in the cisplatin resistance of NSCLC was explored by testing whether N...
Autores principales: | Duan, Shanzhou, Tsai, Ying, Keng, Peter, Chen, Yongbing, Lee, Soo Ok, Chen, Yuhchyau |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695015/ https://www.ncbi.nlm.nih.gov/pubmed/26313152 |
Ejemplares similares
-
Cisplatin treatment increases stemness through upregulation of hypoxia‐inducible factors by interleukin‐6 in non‐small cell lung cancer
por: Zhang, Fuquan, et al.
Publicado: (2016) -
IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer
por: Lee, Soo Ok, et al.
Publicado: (2015) -
IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation
por: Chen, Yuhchyau, et al.
Publicado: (2015) -
Retraction Note to: IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation
por: Chen, Yuhchyau, et al.
Publicado: (2022) -
A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer
por: Yang, Li, et al.
Publicado: (2016)